Mingxin Pharmaceutical Group is a large-scale modern high-tech enterprise deeply engaged in the pharmaceutical industry for more than 30 years. Through continuous innovation and steady development, it has become a highly influential industrial benchmark in the sector.

Founded in 1989 as Jinan Mingxin Pharmaceutical Co., Ltd., the Group successfully completed the restructuring of state-owned enterprise in 2002, marking a new stage of market-oriented operation. After more than 30 years of unremitting efforts and strategic planning, the Group has gradually formed a pattern of multi-entity coordinated development. Its core subsidiaries include Jinan Mingxin Pharmaceutical Co., Ltd., Mingxin Pharmaceutical (Hainan) Co., Ltd., Jinan Xinkang Pharmaceutical Co., Ltd., and Jinan Lantong Biotechnology Co., Ltd. Each entity performs its own functions and complements each other’s advantages, establishing a comprehensive operation system covering key links of the pharmaceutical industry chain.

At present, the Group’s fixed assets reach 480 million yuan, providing solid financial support for R&D innovation, production upgrading and market expansion. Since its establishment, the Group has focused on pharmaceutical APIs and innovative drugs, pursuing excellence in its core business covering pharmaceutical intermediates, APIs and finished preparations. It has formed a full-chain service capability integrating R&D, production, sales and import & export trade, meeting diversified domestic market demands and expanding globally through a mature international layout, providing high-quality and professional pharmaceutical products and services to customers at home and abroad.

Jinan Mingxin Pharmaceutical Co., Ltd. is located in Zhangqiu District, Jinan City, Shandong Province, covering a land area of 88,000 square meters and a building area of 56,000 square meters. The company currently has more than 30 products, with coordinated development of APIs and preparations.

Main APIs include Inosine, Ribavirin, Sildenafil Citrate, Vildagliptin, Terbinafine Hydrochloride, Pantoprazole Sodium, Omeprazole, Metronidazole, Nateglinide, Adenosine Disodium Triphosphate, Inosine Pranobex, etc.Main preparation products include Omeprazole Enteric-coated Capsules, Sildenafil Citrate Tablets, Inosine Tablets, Vonoprazan Fumarate Tablets, Acetylcysteine Granules, Glucosamine Sulfate Capsules, Vildagliptin Tablets, Metronidazole Tablets, Oxymatrine Tablets, etc.

Founded in 2023 and located in Haifu Industrial Park, Qionghai, Hainan, Mingxin Pharmaceutical (Hainan) Co., Ltd. is the first core industrial project put into trial operation in the park. The company has built two GMP-compliant oral solid preparation workshops, equipped with modern warehouses, a comprehensive office building and a central laboratory. Production and testing equipment have reached advanced industry standards, in strict compliance with national Good Manufacturing Practices for pharmaceuticals.

During the trial operation period, the company will focus on optimizing production processes and verifying product quality. Once officially put into production, it will have large-scale production capacity for oral solid preparations, meeting the demand for local medication of common and chronic diseases.

Relying on the policy and geographical advantages of Hainan Free Trade Port, the project helps improve the regional pharmaceutical industry chain, reduce drug supply costs, support pharmaceutical import & export trade and innovative R&D transformation, and promote the cluster-based and high-quality development of Hainan’s biomedical industry.

The company has been successively awarded many honorary titles, including National High-Tech Enterprise, Shandong Provincial Enterprise Technology Center, Shandong Provincial "Specialized, Sophisticated, Unique and New" Small and Medium-sized Enterprise, Shandong Provincial Gazelle Enterprise, Jinan Green Factory, and Jinan "Specialized, Sophisticated, Unique and New" Small and Medium-sized Enterprise.

To promote high-quality development, the Group has established in-depth industry-university-research cooperation with well-known domestic universities and research institutes, continuously enhancing its core competitiveness at an innovative pace of launching two APIs and finished drugs each year. Mingxin Pharmaceutical has now entered a new stage of development.Adhering to the business tenet of "Develop Mingxin Pharmaceutical and Benefit People’s Health", the company unites as one and strives forge ahead, committed to building a first-class large-scale, group-oriented and modern pharmaceutical enterprise.